Order Article Reprints

Attili I, Fuorivia V, Spitaleri G, Corvaja C, Trillo Aliaga P, Del Signore E, Asnaghi R, Carnevale Schianca A, Passaro A, de Marinis F. Alectinib vs. Lorlatinib in the Front-Line Setting for ALK-Rearranged Non-Small-Cell Lung Cancer (NSCLC): A Deep Dive into the Main Differences across ALEX and CROWN Phase 3 Trials. Cancers. 2024; 16(13):2457. https://doi.org/10.3390/cancers16132457

Attili, Ilaria, Valeria Fuorivia, Gianluca Spitaleri, Carla Corvaja, Pamela Trillo Aliaga, Ester Del Signore, Riccardo Asnaghi, Ambra Carnevale Schianca, Antonio Passaro, and Filippo de Marinis. 2024. "Alectinib vs. Lorlatinib in the Front-Line Setting for ALK-Rearranged Non-Small-Cell Lung Cancer (NSCLC): A Deep Dive into the Main Differences across ALEX and CROWN Phase 3 Trials" Cancers 16, no. 13: 2457. https://doi.org/10.3390/cancers16132457

Attili, I., Fuorivia, V., Spitaleri, G., Corvaja, C., Trillo Aliaga, P., Del Signore, E., Asnaghi, R., Carnevale Schianca, A., Passaro, A., & de Marinis, F. (2024). Alectinib vs. Lorlatinib in the Front-Line Setting for ALK-Rearranged Non-Small-Cell Lung Cancer (NSCLC): A Deep Dive into the Main Differences across ALEX and CROWN Phase 3 Trials. Cancers, 16(13), 2457. https://doi.org/10.3390/cancers16132457